Analysts are raising their ratings and price targets on Verve Therapeutics stock today. Verve published very encouraging trial data for its VERVE-102 treatment yesterday. Investors think that the ...

Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should ...

Eric Westin, M.D., promoted to chief medical officer and Jim MacDonald-Clink promoted to senior vice president, head of business development CAMBRIDGE, England & BOSTON, March 27, 2025--(BUSINESS ...

Viking Therapeutics moves toward the head of the pack to become No. 3, but Structure Therapeutics still has a lead in this race. Early this morning, Pfizer announced it will discontinue ...

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific ...

Tvardi Therapeutics, Inc. (Nasdaq: TVRD), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, visits the Nasdaq MarketSite in Times Square.

Get Matt’s next trade alert free. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in ...

During the last three months, 8 analysts shared their evaluations of Bicycle Therapeutics BCYC, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the ...

A source familiar with the situation told the Business Journal that the executive team and board of directors at Lyndra Therapeutics resigned on Tuesday. Lyndra Therapeutics, a drug developer that ...

Shares of NASDAQ:CRSP opened at $41.22 on Monday. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $73.09. The company’s 50-day moving average price is $43.09 and its ...